Both 2,5-dimethylcelecoxib (DMC) (an mPGES-1 inhibitor) and atezolizumab (a monoclonal antibody that targets PD-L1 and is used in the treatment of metastatic urothelial carcinoma, triple-negative breast cancer, and non-small-cell lung cancer [91,92]) counteracted this immunosuppressive effect by attracting CD8+ cells and repressing the expression of PD-L1 and CD163, as it was shown in mice with HBx(+) HCC. This evidence concerns the gene CD8A and hepatocellular carcinoma.